| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11253504 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US10398686 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9592227 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9744163 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US9913909 | HERON THERAPS INC | Compositions of a polyorthoester and an aprotic solvent |
Mar, 2034
(9 years from now) | |
| US11083730 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10980886 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2035
(10 years from now) | |
| US9694079 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US9801945 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10098957 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10213510 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10632199 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US10898575 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11413350 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11083797 | HERON THERAPS INC | Long-acting polymeric delivery systems |
Apr, 2035
(10 years from now) | |
| US11844837 | HERON THERAPS INC | Compositions of a polyorthoester and an organic acid excipient |
Apr, 2036
(11 years from now) | |
Zynrelef Kit is owned by Heron Theraps Inc.
Zynrelef Kit contains Bupivacaine; Meloxicam.
Zynrelef Kit has a total of 16 drug patents out of which 0 drug patents have expired.
Zynrelef Kit was authorised for market use on 12 May, 2021.
Zynrelef Kit is available in solution, extended release;periarticular dosage forms.
Zynrelef Kit can be used as treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation, treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures via instillation.
The generics of Zynrelef Kit are possible to be released after 21 April, 2036.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | May 12, 2024 |
| New Indication(I-933) | Jan 23, 2027 |
Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient
Market Authorisation Date: 12 May, 2021
Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarti...
Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR
ZYNRELEF KIT family patents
